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Impact of probiotic intake on the glycemic 
control, lipid profile and inflammatory  
markers among patients with type 2  
diabetes mellitus
ABSTRACT
Background. Type 2 diabetes mellitus (T2DM) is a 
chronic disease with many dramatic complications. 
It has also been suggested that altered intestinal 
microbiota leads to increased intestinal permeability 
and mucosal immune response, contributing to the 
development of diabetes. We aimed to investigate 
the effect of introduction of probiotic products on 
glycemic control and inflammatory markers among 
patients with T2DM.
Methods. The present work was carried on 150 patients 
with T2DM. The studied patients were subjected to 
full history taking, clinical examination and laboratory 
investigations including fasting blood glucose (FBG), 
2 hours post prandial blood glucose (2hPP), glycated 
hemoglobin (HbA1c), total cholesterol (TC), triglycer-
ides (TG), HDL-C, LDL-C, C-reactive protein (CRP), inter-
leukin 6 (IL6) and tumor-necrosis factor alpha (TNF α). 
They were divided into 3 groups each of 50 patients. 
They were all instructed to eat well-balanced diet. The 
first group was instructed to eat the well-balanced diet 
only, the second group received 2 cups of yogurt daily 
in addition to diet and the third group received one 
teaspoonful yeast daily in addition to diet. The effect 
of the intervention was evaluated after 16 weeks.
Results. Patients receiving yogurt and the patients 
receiving yeast showed significant reduction of FBG, 
HbA1c, IL6, TNF-a, CRP and significant elevation of 
HDL-C compared to patients on diet only. The 3 groups 
showed significant reduction in 2hPP blood glucose 
and LDL-C.
Conclusion. Probiotic intake in patients with T2DM has 
beneficial effect on glycemic control, lipid profile and 
inflammatory markers after 16 weeks. (Clin Diabetol 
2021; 10)
Key words: type 2 diabetes, probiotics, lipid profile, 
inflammatory markers, yeast
Introduction
Diabetes mellitus is one of the most common 
chronic diseases in nearly all countries, and continues 
to increase in number and significance, especially with 
changing lifestyles leading to reduced physical activity 
and increased obesity [1, 2].
Type 2 diabetes mellitus (T2DM) is a metabolic 
disorder characterized by hyperglycemia in addition to 
altered lipid and protein metabolism caused by variable 
degrees of insulin resistance, impaired insulin secretion 
and increased glucose production [3, 4].
Accumulating evidence shows that inflammation 
plays a crucial intermediary role in the pathogenesis 
of T2DM, thus relating diabetes to a number of com-
monly coexisting conditions thought to originate via 
inflammatory mechanisms [5]. In this regard, more data 
suggest that interleukin-6 (IL-6) and C-reactive protein 
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(CRP) are associated with type 2 diabetes [6]. Several 
studies indicated that increased levels of cytokines and 
acute-phase proteins can participate in maintaining the 
insulin-resistant state [7–10].
T2DM affects the immune system of the body and 
these immunological changes affect the cytokine re-
lease which alter the leukocytes and result in increased 
apoptosis. These changes suggest the involvement of 
inflammation in the pathogenesis of T2DM [11]. Pro-
inflammatory cytokines and acute phase reactants are 
involved in multiple metabolic pathways relevant to 
insulin resistance, including insulin regulation, reactive 
oxygen species, lipoprotein lipase action and adipocyte 
function [12]. Inflammation is considered as a key fac-
tor in the pathogenesis of T2DM, but what triggers 
this inflammation is still unknown; however, obesity is 
considered an important factor [13, 14].
The gut microbiota comprises approximately 1014 
organisms, which in human adults are mainly represent-
ed by members of the phyla: bacteroides, sclerenchyma, 
actinomycetes, proteus, and verrucous microflora. The 
exact microbiome composition varies greatly between 
individuals [15]. Gut microbes are key to many aspects 
of human health, including immune and metabolic 
functions, and evidence supports the important role 
of gut microbiota in human health [16, 17].
Homeostasis of microbiota in the gut is vital for 
maintenance of the host immunity and there has been 
evidence demonstrating that changes in the composi-
tion of gut microbiota could play a role in the patho-
genesis of T2DM [18, 19]. Dysbiotic gut microbiota 
affects gut permeability and promotes inflammation in 
T2DM as the intestinal barrier is disturbed by microbial 
product – lipopolysaccharide (LPS).  The LPS released 
from the gut into the circulation causes “metabolic 
endotoxemia” which is a state of low-grade systemic 
inflammation [18, 20, 21].
Yeasts are eukaryotic microorganisms classified as 
members of the fungus kingdom with 1,500 species 
currently identified and are estimated to constitute 
1% of all described fungal species [22]. Yeasts are 
unicellular, although some species may also develop 
multicellular characteristics by forming strings of con-
nected budding cells known as pseudohyphae or false 
hyphae [22].
Probiotics are live microorganisms that, when 
administered in adequate amounts, confer a health 
benefit on the host [23]. While most well-characterized 
probiotic microbes are bacteria, certain yeasts have 
been shown to have health benefits across various 
studies [24]. Different yeast species such as Sac-
charomyces cerevisiae, Saccharomyces boulardi and 
some strains of Candida are recognized as yeasts with 
probiotic potential [25, 26]. Evidence is available on 
the anti-inflammatory properties of probiotics and 
some researches showed beneficial use of probiotics 
in T2DM [27]. Animal studies showed that Lactobacil-
lus GG treatment not only reduces glucose intolerance 
but also significantly decrease hyperglycemia in strep-
tozotocin induced diabetes rats [28]. It has also been 
demonstrated that probiotics can decrease the blood 
glucose in animal models through reduction of inflam-
mation and prevention of b-cell destruction [29]. Yun 
et al. [30] reported a significant reduction in fasting 
and postprandial glucose and a decrease in HbA1c in 
probiotic treated rats. However, human clinical studies 
using various probiotics have yielded mixed results. 
A meta-analysis by Yao et al. [31] demonstrated that 
probiotics supplementation was associated with sig-
nificant improvement in HbA1c and fasting insulin in 
patients with T2DM. Other meta-analyses revealed that 
probiotic supplementation beneficial affects insulin 
resistance and glycated hemoglobin levels [32, 33].
The aim of this study was to assess the effect of 
probiotic yoghurt and yeast intake on the inflamma-
tory markers, glycemic control and lipid profile among 
patients with T2DM.
Material and methods
The study was carried out on 150 patients with 
T2DM and the duration of the study was 16 weeks. 
The study included male and female patients aged 21 
years and older with T2DM who agreed to participate 
in this study. The cases were recruited from the out-
patient clinic of diabetes in Alexandria Main University 
Hospital. Patients with coronary heart diseases, history 
or presence of cancer, patients with lactose intoler-
ance, patients with thyroid disorders, and pregnant 
and lactating women were excluded from this study.
All the participants included in the study were 
informed about the nature of the study, and their 
oral and written consent on participating voluntarily 
were obtained and the approval of ethics committee 
of Alexandria faculty of medicine was also obtained.
Full medical history, drug history (nutritional sup-
plements, drugs of weight reduction and drugs for 
chronic diseases), diabetes history (age of onset of the 
disease, drugs taken, trials of diet regimens and family 
history of diabetes) and finally dietary habits (number 
of main meals and snacks, fast-food consumption, 
and fat consumption) were obtained from all studies 
subjects. Anthropometric measurements were done 
including height, weight, body mass index (BMI) and 
waist circumference.
The 150 diabetic patients were divided into 3 
groups with 50 persons in each group. Patients in 
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Group 1 were instructed by the researcher to eat well 
balanced diet, based on the subject’s measured pre-
treatment resting energy expenditure, designed to pro-
vide 45–65% of energy from carbohydrates, 10–35% 
of energy from proteins and 20–35% of energy derived 
from fat. The resting energy expenditure is estimated 
using the Mifflin-St Jeor equation [34]. Subjects were 
advised to exercise or walk 30 minutes per day, five 
days a week. Group 2, the same as the first group 
plus the intake of two cups of yogurt provided by the 
researchers daily. The yogurt used in the study was 
fortified by probiotic strains (Bifidobacterium animalis 
dn-173 010). Group 3, the same as the first group plus 
a supplement in the form of one teaspoonful of natural 
baking yeast daily containing Saccharomyces cerevisiae 
before lunch, provided by the researchers. Group 1 was 
considered as the control group while groups 2 and 3 
were considered to be the experimental groups.
Laboratory investigations were performed for every 
patient at the beginning and after 8 and 16 weeks of 
the study including fasting blood glucose level ( FBG), 
two hours post prandial blood glucose level (2hPP) 
which was performed 2 hours after breakfast using 
a sample of venous blood, total cholesterol (TC) and 
triglyceride (TG) serum level, HDL-C, LDL-C levels, C-
reactive protein (CRP) level, interleukin 6 (IL6) level, 
tumor necrosis factor alpha (TNF α) level and glycated 
hemoglobin (HbA1c).
After 16 weeks of the study, reassessment of the 
change of the outcome after the intervention on the 
anthropometric measurements and all parameters of 
laboratory investigations were performed.
Results
The studied subjects were divided into 3 groups. 
There was no significant difference between studied 
groups regarding age and male to female ratio. The 
basic characteristics of the studied subjects are de-
scribed in Table 1.
As shown in Tables 2 and 3, after 16 weeks of 
intervention the three groups showed significant re-
duction in the 2 hours postprandial blood glucose level 
but the reduction was higher among yogurt and yeast 
groups compared to diet only (P < 0.001, P < 0.001 
respectively) and there was no significant difference 
between yogurt group and yeast group (P = 0.836). 
However, only the patients receiving yogurt and the 
patients receiving yeast showed significant reduction 
in FBG and HbA1c levels with no significant difference 
in reduction in FBG and HbA1c between both groups 
(P = 0.933, P = 0.397 respectively) while there was no 
significant change in FBG and HbA1c levels in patients 
receiving diet only.
Regarding the lipid profile, after 16 weeks, the 
three groups showed significant reduction in the level 
of total cholesterol and LDL-C levels but the reduction 
in total cholesterol was higher in yogurt and yeast 
groups compared to diet only (P < 0.001, P < 0.001 
respectively) and there was no significant difference in 
the reduction of LDL-C among the three groups. Only 
the patients receiving yogurt and the patients receiving 
yeast showed significant rise in HDL-C levels with no 
significant difference in elevation of HDL-C between 
both groups (P = 0.948) while there was no significant 
change in HDL-C level in patients receiving diet only. On 
the other hand, patients receiving yogurt in addition 
to diet showed significant reduction in serum triglyc-
erides level while there was no significant change in 
the triglyceride level in the other 2 groups.
Regarding the inflammatory markers, after 16 
weeks, the patients receiving yogurt and the patients 
receiving yeast showed significant reduction in CRP 
level, IL-6 level, and TNF-a levels, but there was no sig-
nificant change in their levels in patients receiving diet 
only. There was no significant difference between the 
yogurt and yeast groups regarding reduction in CRP and 
IL-6 levels (P = 0.557, and P = 0.807 respectively) while 
the reduction in TNF-a was higher in patients receiving 
yogurt compared to those receiving yeast (P < 0.001).
Discussion
Recent studies indicate that gut microbiota play 
an important role in the pathogenesis of T2DM. As an 
effective means of regulating gut microbiota, probiotics 
are live micro-organisms that are believed to provide 
a specific health benefit on the host. Whether probiotic 
supplementation could improve metabolic profiles 
by modifying gut microbiota in T2DM or not is still 
controversial [35].
The gut microbiota could influence inflammatory 
pathways and energy metabolism of the host, in other 
words, dysbiotic gut microbiota could affect glucose, 
lipid metabolism, and insulin action [36, 37]. More and 
more studies showed that probiotics could change the 
gut flora, improve total cholesterol and low-density 
lipoprotein cholesterol levels, and reduce blood glucose 
level and insulin resistance [37–39].
In the current study, efforts were done to record 
the effect of intake of different types of probiotics on 
many parameters of patients with T2DM through the 
introduction of two types of probiotics using yogurt and 
yeast. The yoghurt used in the study contained a pro-
biotic strain known as Bifidobacterium animalis dn-173 
010 and the yeast contained Saccharomyces cerevisiae.
In our study, there was a statistically significant 
reduction in FBG, 2 hPP glucose level and glycated 
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hemoglobin level in the patients who received probiotic 
yogurt alone or yeast on a daily basis. 
This partially agrees with a meta-analysis in which 
a total of 12 randomized controlled trials were included. 
Probiotics could improve FBG but there were no sig-
nificant differences in HbA1c and HOMA-IR between the 
treatment group and the control group [35]. Another 
meta-analysis of 12 randomized controlled trials con-
cluded that probiotics could reduce FBG levels by around 
15 mg/dL and HbA1c by 0.54%, along with a significant 
improvement of 0.98 in HOMA-IR values, indicating 
a modest effect on glycemic control. This analysis eluci-
dated that probiotics may improve glycemic control in 
T2DM [33]. Another study by Yun et al. [30] found that 
probiotic administration of Bifidobacterium for 1 month 
in mice with high-fat diet-induced diabetes normalized 
the glucose metabolism. This was documented by the 
lowering of fasting insulin levels, blunting of glucose 
excursions on the intraperitoneal glucose tolerance test, 
and increase in the glucose turnover rate.
In our study total cholesterol and LDL-C levels 
were reduced in the three groups with higher reduc-
tion in total cholesterol in patients receiving probiotics 
compared to those who didn’t receive probiotics. Also, 
HDL-C levels were elevated in patients receiving yogurt 
or yeast on a daily basis compared to those who didn’t 
receive them while beneficial effect on triglycerides 
levels was shown with yogurt only. These data agrees 
with a study by Ejtahed et al. [40] in which probiotic 
yogurt consumption caused a 4.54% decrease in total 
cholesterol and a 7.45% decrease in LDL-C compared 
with the control group. 
Table 1. Basic characteristics of the studied groups
Yogurt and diet 
(n = 50)






Mean ± SD 48.3 ± 12.9 48.6 ± 11.5 46.4 ± 13.2 0.992 0.730 0.656
Weight [kg]
Mean ± SD 86.7 ± 15.3 81.8 ± 14.9 89 ± 16 0.260 0.733 0.055
BMI [kg/m2]
Mean ± SD 31.1 ± 5.3 28.5 ± 7.6 30.2 ± 6 0.102 0.765 0.363
FBG [mg/dL]
Mean ± SD 139.6 ± 33.1 137.5 ± 32.6 136 ± 24 0.937 0.823 0.966
2hPP [mg/dL]
Mean ± SD 224.2 ± 38.7 231 ± 34.7 221.8 ± 18.4 0.539 0.925 0.323
HbA1c (%)
Mean ± SD 8.2 ± 1.4 8.2 ± 1.4 8 ± 1.2 0.999 0.610 0.638
Total cholesterol [mg/dL]
Mean ± SD 273.8 ± 49.3 272.5 ± 25.9 268 ± 25.9 0.981 0.689 0.800
TG [mg/dL]
Mean ± SD 179 ± 39.9 177.2 ± 29.4 166.3 ± 23.9 0.959 0.115 0.199
HDL-C [mg/dL]
Mean ± SD 43.4 ± 3.3 43.6 ± 4.1 45.1 ± 5.5 0.972 0.113 0.178
LDL-C [mg/dL]
Mean ± SD 121.4 ± 17.5 118.4 ± 16.5 114.7 ± 5.7 0.553 0.053 0.394
CRP [mg/dL]
Mean ± SD 10.8 ± 5.2 10.9 ± 3.8 9.2 ± 3.3 0.204 0.439 0.025
IL6 [mg/dL]
Mean ± SD 50.2 ± 24.3 43.1 ± 15.7 43.5 ± 14.9 0.432 0.605 0.815
TNF-a [mg/dL]
Mean ± SD 21.2 ± 4.5 20.2 ± 3 17.3 ± 0.5 0.609 0.001 0.001
2hPP: 2 hours postprandial blood glucose; BMI: body mass index; CRP: C-reactive protein; FBG: fasting blood glucose; HbA1c: glycated hemoglobin; HDL-C: 
high-density lipoprotein cholesterol; IL-6: interleukin 6; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; TNF-α: tumor necrosis factor alpha
P1: P value for comparing between Yogurt and diet group and Yeast and diet group
P2: P value for comparing between Yogurt and diet group and Diet only group
P3: P value for comparing between Yeast and diet group and Diet only group
Statistically significant at P ≤ 0.0
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Table 2. Effect of the intervention on different studied parameters after 16 weeks
Baseline After 16 weeks P
FBG [mg/dL]
Yogurt and diet (n = 50)
Mean ± SD 139.6 ± 33.1 111.3 ± 21.8 < 0.001*
Yeast and diet (n = 50)
Mean ± SD 137.5 ± 32.6 112.9 ± 24.2 < 0.001*
Diet only (n = 50)
Mean ± SD 136 ± 24 133.6 ± 21.4 1.000
2 hPP [mg/dL]
Yogurt and diet (n = 50)
Mean ± SD 224.2 ± 38.7 163.3 ± 25.9 < 0.001*
Yeast and diet (n = 50)
Mean ± SD 231 ± 34.7 160.7 ± 18.3 < 0.001*
Diet only (n = 50)
Mean ± SD 221.8 ± 18.4 190.2 ± 22.5 0.001*
HbA1c (%)
Yogurt and diet (n = 50)
Mean ± SD 8.2 ± 1.4 6.9 ± 1.3 < 0.001*
Yeast and diet (n = 50)
Mean ± SD 8.2 ± 1.4 7.2 ± 1.3 < 0.001*
Diet only (n = 50)
Mean ± SD 8 ± 1.2 8.2 ± 0.8 0.377
Total cholesterol (mg/dL)
Yogurt and diet (n = 50)
Mean ± SD 273.8 ± 49.3 201.2 ± 26.6 < 0.001*
Yeast and diet (n = 50)
Mean ± SD 272.5 ± 25.9 193 ± 21.4 < 0.001*
Diet only (n = 50)
Mean ± SD 268 ± 25.9 241 ± 33.4 < 0.001*
TG [mg/dL]
Yogurt and diet (n = 50)
Mean ± SD 179 ± 39.9 131.6 ± 26.6 < 0.001*
Yeast and diet (n = 50)
Mean ± SD 177.2 ± 29.4 166.1 ± 26.7 0.073
Diet only (n = 50)
Mean ± SD 166.3 ± 23.9 151 ± 29.2 0. 067
HDL-C [mg/dL]
Yogurt and diet (n = 50)
Mean ± SD 43.4 ± 3.3 55.8 ± 4.1 < 0.001*
Yeast and diet (n = 50)
Mean ± SD 43.6 ± 4.1 55.5 ± 4.2 < 0.001*
Diet only (n = 50)
Mean ± SD
LDL-C [mg/dL] 45.1 ± 5.5 45.3 ± 5.1 1.000
Yogurt and diet (n = 50)
Mean ± SD 121.4 ± 17.5 105.3 ± 13.2 < 0.001*
Yeast and diet (n = 50)
Mean ± SD 118.4 ± 16.5 105.2 ± 17.5 < 0.001*
Diet only (n = 50)
Mean ± SD 114.7 ± 5.7 107.7 ± 7.6 < 0.001*
CRP [mg/dL]
Yogurt and diet (n = 50)
Mean ± SD 10.8 ± 5.2 4.6 ± 2.4 < 0.001*
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Table 2. Effect of the intervention on different studied parameters after 16 weeks
Baseline After 16 weeks P
Yeast and diet (n = 50)
Mean ± SD 10.9 ± 3.8 5 ± 2.8 < 0.001*
Diet only (n = 50)
Mean ± SD 9.2 ± 3.3 8.2 ± 5.1 0.064
IL6 [mg/dL]
Yogurt and diet (n = 50)
Mean ± SD 50.2 ± 24.3 31.5 ± 14.4 < 0.001*
Yeast and diet (n = 50)
Mean ± SD 43.1 ± 15.7 31.7 ± 12 < 0.001*
Diet only (n = 50)
Mean ± SD 43.5 ± 14.9 43.1 ± 16.3 0.058
TNF-α [mg/dL]
Yogurt and diet (n = 50)
Mean ± SD 21.2 ± 4.5 16.5 ± 1.5 < 0.001*
Yeast and diet (n = 50)
Mean ± SD 20.2 ± 3 17.1 ± 1 < 0.001*
Diet only (n = 50)
Mean ± SD 17.3 ± 0.5 18.1 ± 0.8 0.055
2hPP: 2 hours postprandial blood glucose; BMI: body mass index; CRP: C-reactive protein; FBG: fasting blood glucose; HbA1c: glycated hemoglobin;  
HDL-C: high-density lipoprotein cholesterol; IL6: interleukin 6; LDL-C: low-density lipoprotein cholesterol
TG: triglycerides; TNF-a: tumor necrosis factor alpha; *Statistically significant at p ≤ 0.05
Table 3. Comparison of the laboratory parameters in the three groups after 16 weeks of intervention
Yogurt and diet 
(n = 50)






Mean ± SD 111.3 ± 21.8 112.9 ± 24.2 133.6 ± 21.4 0.933 < 0.001 < 0.001
2hPP [mg/dL]
Mean ± SD 163.3 ± 25.9 160.7 ± 18.3 190.2 ± 22.5 0.836 < 0.001 < 0.001
HbA1c (%)
Mean ± SD 6.9 ± 1.3 7.2 ± 1.3 8.2 ± 0.8 0.397 < 0.001 < 0.001
Total cholesterol [mg/dL]
Mean ± SD 201.2 ± 26.6 193 ± 21.4 241 ± 33.4 0.304 < 0.001 < 0.001
TG [mg/dL]
Mean ± SD 131.6 ± 26.6 166.1 ± 26.7 151 ± 29.2 < 0.001 0.002 0.0581
HDL-C [mg/dL]
Mean ± SD 55.8 ± 4.1 55.5 ± 4.2 45.3 ± 5.1 0.948 < 0.001 < 0.001
LDL-C [mg/dL]
Mean ± SD 105.3 ± 13.2 105.2 ± 17.5 107.7 ± 7.6 0.999 0.653 0.624
CRP [mg/dL]
Mean ± SD 4.6 ± 2.4 5 ± 2.8 8.2 ± 5.1 0.557 < 0.001 < 0.001
IL6 [mg/dL]
Mean ± SD 31.5 ± 14.4 31.7 ± 12 43.1 ± 16.3 0.807 < 0.001 < 0.001
TNF-a [mg/dL]
Mean ± SD 16.5 ± 1.5 17.1 ± 1 18.1 ± 0.8 < 0.001 < 0.001 < 0.001
2hPP: 2 hours postprandial blood glucose; BMI: body mass index; CRP: C-reactive protein; FBG: fasting blood glucose; HbA1c: glycated hemoglobin;  
HDL-C: high-density lipoprotein cholesterol; IL6: interleukin 6; LDL-C: low-density lipoprotein cholesterol
TG: triglycerides; TNF-a: tumor necrosis factor alpha
P1: P value for comparing between Yogurt and diet group and Yeast and diet group
P2: P value for comparing between Yogurt and diet group and Diet only group
P3: P value for comparing between Yeast and diet group and Diet only group
Statistically significant at P ≤ 0.05
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The results of a meta-analysis including twelve RCTs 
involving 770 participants by Hu et al. [41] showed that 
probiotics could significantly reduce fasting blood glu-
cose and HOMA-IR of patients with T2DM. Results also 
confirmed the significant lowering effect of probiotics 
on total cholesterol and as well as the elevating effect 
on HDL-c but with no significant change on LDL-C.
As the gut microbiota is a main source of endo-
toxin, treatment with probiotics may influence the 
circulating levels of endotoxin by altering the micro-
biota composition. To date, relatively few studies have 
examined the effects of endotoxin in metabolic diseases 
using probiotics. To expand on these earlier findings, 
the present study explored the potential beneficial ef-
fects of probiotics on circulating endotoxin levels and 
other markers for systemic low-grade inflammation in 
patients with T2DM.
In our study all aspects of inflammatory markers 
which were investigated were changed in the patients 
who had probiotics. CRP, IL-6 and TNF-α levels were 
reduced significantly in both groups who received 
probiotics on a daily basis with no reduction in those 
who didn’t receive probiotics. Our study agrees with 
a double-blind, placebo-controlled trial that showed 
that the serum concentrations of hs-CRP, IL-6 and TNF-α 
decreased significantly in patients receiving synbiotics 
for 8 weeks compared to baseline [42].
Probiotic bacteria (with the best documented 
strains being species of Lactobacillus or Bifidobacte-
rium) can inhibit the growth of pathogenic bacteria by 
acidifying the gut lumen, competing for nutrients, and 
producing antimicrobial substances. Furthermore, they 
adhere to the gastrointestinal mucosa and are thought 
to prevent bacterial translocation from the gut [43, 44]. 
However, not all studies have shown beneficial effects 
of probiotics, and thus caution should be taken in terms 
of the dosage and strains to be used, as these may 
have important ramifications on the effects observed. 
Conclusion
In summary, we expect that our findings will dem-
onstrate that probiotics alter gut microbiota in T2DM 
and that, in theory, the alterations will be metabolically 
favorable with continued probiotic use. The results of 
our study showed that the administration of probiot-
ics daily for 16 weeks could result in improvement of 
FBG, postprandial blood glucose, HbA1c, lipid profile 
and reduction in inflammatory markers in patients 
with T2DM and thus probiotics can be a promising 
beneficial adjuvant in T2DM. However, further studies 
on larger scales will be needed to demonstrate whether 
the efficacy of the probiotics used in this study can be 
extended further levels. 
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